https://www.ncbi.nlm.nih.gov/books/NBK431102/

Colchicine has FDA approval for gout prophylaxis and treatment of acute gouty flares. It also has approval for the treatment of familial Mediterranean fever.[1][2]

While not approved for the following conditions, colchicine has been used off-label to treat the following:

Acute and recurrent pericarditis
Prevention of post pericardial syndrome
Primary biliary cirrhosis
Hepatic cirrhosis
Dermatitis herpetiformis
Paget’s disease of bone
Chronic immune thrombocytopenia and idiopathic thrombocytopenic purpura
Pseudogout
Idiopathic pulmonary fibrosis
Recommendations for colchicine do not include prophylaxis or treatment of gout flares in the pediatric population. It can be used to treat familial Mediterranean fever in children four years of age and older.

Go to:
Mechanism of Action
Colchicine has primarily anti-inflammatory properties. It disrupts cytoskeletal functions by inhibiting beta-tubulin polymerization into microtubules, preventing activation, degranulation, and migration of neutrophils associated with mediating some gout symptoms. Colchicine does not inhibit phagocytosis of uric acid crystals, but it does seem to prevent the release of an inflammatory glycoprotein from phagocytes. Colchicine blocks metaphase due to two separate anti-mitotic effects; disruption of mitotic spindle formation and disruption of the sol-gel formation. The toxic effects of colchicine are related to this anti-mitotic activity within proliferating tissue such as skin, hair, and bone marrow.[3][4]

The mechanism of action of colchicine in the treatment of familial Mediterranean fever is less well understood; it may interfere with intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediate the activation or interleukin-1-beta.